Clinical trial · Observational
CD155 in Bladder Cancer
Predictive Value of CD155 for Survival and Effectiveness of Chemotherapy in Patients With Muscle Invasive Bladder Cancer
NCT03789682CI-TRIAL-00088588completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adjuvant chemotherapy | Drug | Adjuvant Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- FUSCC cystectomy cohort
- description
- patients underwent cystectomy in Fudan University Shanghai Cancer Center
- interventionNames
- Drug: Adjuvant chemotherapy
Primary outcomes (1)
- measure
- Recurrence free survival
- timeFrame
- 2018.1.1-2023.12.31
- description
- Time to recurrence or metastasis
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 2018.1.1-2028.1.1
- description
- Time to death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * patients with non-metastatic muscle invasive bladder cancer * pathology confirmed urothelial carcinoma * underwent cystectomy and pelvic lymph node dissection Exclusion Criteria: * not enough tissue for immunohistochemistry * patients with a second neoplasm
References
Publications (0)
Data not yet available
No reference posted for this study.